Novartis AG Common Stock (NVS)

The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage.

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

Exploring NOVARTIS AG-SPONSORED ADR's Technical Signals and Breakout Potential: Promising Signs: NOVARTIS AG-SPONSORED ADR Setting the Stage for a Breakout.

In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off.

FDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy.

NOVARTIS AG-SPONSORED ADR has caught the attention as a great value stock. NYSE:NVS excels in profitability, solvency, and liquidity, all while being very reasonably priced.

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.

Monte Rosa's MRT-6160 shows promising Phase 1 results, with Novartis backing its development in a deal that could reach $2.1B in milestone payments.

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.

Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support.

Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday.

Uncover the potential of NOVARTIS AG-SPONSORED ADR, an undervalued stock. NYSE:NVS maintains a strong financial position and offers an appealing valuation.

Highly ranked Novartis is forming the right side of a long cup base with a buy point of 120.92. And it's literally running higher.

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.

A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not impose unconstitutional fines, takings, or compelled speech.

Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing the impact.

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its cardiovascular portfolio.

The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads.